DUBLIN--(BUSINESS WIRE)--The "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report offers comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection pipeline products by developmental stage, product type, molecule type, and administration route.
Key Topics Covered
1. Report Introduction
2. Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
Companies Featured
- Atriva Therapeutics GmbH
- Autoimmune Technologies LLC
- CEL-SCI Corp.
- Fab'entech S.A.
- GeneCure LLC
- Nanotherapeutics Inc.
- Novavax Inc.
- Oncovir Inc.
- Phelix Therapeutics LLC
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/6dw954/severe_acute?w=4
